For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE® Ultra Human CXCL1/GRO-α Detection Kit is designed for detection and quantitation of human CXCL1 (GRO-α) in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
C-X-C Motif Chemokine 1 (CXCL1) is an 11 kDa chemokine and is part of the intercrine alpha (chemokine CXC) family. The secreted protein is proteolytically processed at the N-terminus and the processed form is usually referred to as GRO-α. CXCL1 is expressed by macrophages, neutrophils and epithelial cells. Its synthesis is induced by a variety of inflammatory mediators such as PDGF, M-CSF, TNFα, LPS, and TLR 4. The major role of CXCL1 is its chemoacttractant activity on neutrophils. CXCL1 plays a role in inflammation and exerts its effects on endothelial cells in an autocrine way. CXCL1 is implicated in spinal cord development, angiogenesis, inflammation, wound healing, and tumorigenesis. CXCL1 is overexpressed in invasive bladder cancer and is secreted by human melanoma cells.
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Unit Size||10,000 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.